Display options
Cite
Arriola E, Wheater M, Krishnan R, et al. Immunosuppression for ipilimumab-related toxicity can cause . Oncoimmunology. 2015;4(10):e1040218doi: 10.1080/2162402X.2015.1040218.
Arriola, E., Wheater, M., Krishnan, R., Smart, J., Foria, V., & Ottensmeier, C. (2015). Immunosuppression for ipilimumab-related toxicity can cause . Oncoimmunology, 4(10), e1040218. https://doi.org/10.1080/2162402X.2015.1040218
Arriola, Edurne, et al. "Immunosuppression for ipilimumab-related toxicity can cause ." Oncoimmunology vol. 4,10 (2015): e1040218. doi: https://doi.org/10.1080/2162402X.2015.1040218
Arriola E, Wheater M, Krishnan R, Smart J, Foria V, Ottensmeier C. Immunosuppression for ipilimumab-related toxicity can cause . Oncoimmunology. 2015 May 27;4(10):e1040218. doi: 10.1080/2162402X.2015.1040218. eCollection 2015 Oct. PMID: 26451305; PMCID: PMC4589063.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2015 May 27;4(10):e1040218. doi: 10.1080/2162402X.2015.1040218. eCollection 2015 Oct.

Immunosuppression for ipilimumab-related toxicity can cause .

Oncoimmunology

Edurne Arriola, Matthew Wheater, Radhika Krishnan, James Smart, Vipul Foria, Christian Ottensmeier

Affiliations

  1. Cancer Sciences Unit; University of Southampton and University Hospital Southampton NHS Foundation Trust ; Southampton, UK ; University Hospital Southampton NHS Foundation Trust ; Southampton, UK ; Southampton Experimental Cancer Medicine Center; University of Southampton and University Hospital Southampton NHS Foundation Trust ; Southampton, UK.
  2. University Hospital Southampton NHS Foundation Trust ; Southampton, UK ; Southampton Experimental Cancer Medicine Center; University of Southampton and University Hospital Southampton NHS Foundation Trust ; Southampton, UK.
  3. University Hospital Southampton NHS Foundation Trust ; Southampton, UK.

PMID: 26451305 PMCID: PMC4589063 DOI: 10.1080/2162402X.2015.1040218

Abstract

Ipilimumab is a standard therapy for advanced melanoma. Severe immune related adverse events occur in up to 30% of patients and require treatment with immunosuppressants such as steroids or the anti-TNFα antibody, infliximab. We describe two patients with advanced melanoma treated with ipilimumab. Both suffered from severe immune related side effects and required prolonged immunosuppression with steroids and/or infliximab. Both patients recovered and in spite of the immune suppression, demonstrate clinical evidence of tumor control. This argues that distinct immunological effector functions control nosocomial infection and tumor, respectively. To our knowledge, these are also the first two case reports of pneumocystis pneumonia in this setting.

Keywords: immunosuppression; infliximab; ipilimumab; melanoma; opportunistic; pneumocystis; pneumonia; steroids

References

  1. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6681-8 - PubMed
  2. Am Soc Clin Oncol Educ Book. 2012;:174-7 - PubMed
  3. J Immunother Cancer. 2014 Jun 18;2:19 - PubMed
  4. J Immunol. 2006 May 15;176(10):6147-54 - PubMed
  5. Emerg Infect Dis. 2013 Mar;19(3):386-92 - PubMed
  6. J Clin Invest. 1997 May 1;99(9):2110-7 - PubMed
  7. Sci Transl Med. 2014 Sep 17;6(254):254ra128 - PubMed
  8. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  9. Dig Dis Sci. 2010 May;55(5):1396-405 - PubMed
  10. Semin Immunopathol. 2015 Mar;37(2):153-62 - PubMed
  11. Oncologist. 2013 Jun;18(6):733-43 - PubMed
  12. Nature. 2014 Nov 27;515(7528):558-62 - PubMed
  13. Emerg Infect Dis. 2004 Oct;10 (10 ):1713-20 - PubMed
  14. Clin Immunol. 2008 Feb;126(2):121-36 - PubMed
  15. Autoimmun Rev. 2011 Apr;10(6):305-10 - PubMed

Publication Types

Grant support